ZC-B, also known as 3-(4-bromo-2,5-dimethoxyphenyl)azetidine or as 2C-B-AZET, is a phenethylamine derivative which acts as a serotonin receptor agonist selective for the 5-HT2 subtypes, with an EC50 of 1.6 nM at 5-HT2A, vs 5.8 nM at 5-HT2C. It is structurally related to the psychedelic phenethylamines 2C-B and DOB, but with the amine side chain conformationally restricted as an azetidine ring.[1][2][3]

See also

References

  1. ↑ US 2021/0137908, Kristensen JL, Jensen AA, Märcher-Rørsted E, "5-HT2A Agonists for Use in Treatment of Depression.", published 13 May 2021, assigned to Lophora ApS.
  2. ↑ WO 2022/221774, Johnson G, Nichols DE, Maillet EL, "Aryl-ring-substituted 3-phenylazetidines and their use in methods for treating 5-HT2 responsive conditions", published 2022-10-20, assigned to leusis Therapeutics US Inc.
  3. ↑ Sabnis RW (September 2025). "Novel Compounds as 5‑HT2A Agonists for Treating Depression". ACS Medicinal Chemistry Letters. 16 (9): 1709–1710. doi:10.1021/acsmedchemlett.5c00461. PMID 40959260.
source: https://en.wikipedia.org/wiki/ZC-B